GBDC Stock +24.76% Since The Golden Star Was Identified GBDC Stock +24.76% Since The Golden Star Was Identified Unlock Golden Star List
RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of EXEL
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Exelixis stock price up 0.219% on Wednesday
(Updated on Apr 17, 2024)

Sell candidate since Apr 11, 2024 Gain 0.97% PDF

The Exelixis stock price gained 0.219% on the last trading day (Wednesday, 17th Apr 2024), rising from $22.82 to $22.87. During the last trading day the stock fluctuated 2.04% from a day low at $22.83 to a day high of $23.29. The price has been going up and down for this period, and there has been a -3.46% loss for the last 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 1 million more shares were traded than the day before. In total, 3 million shares were bought and sold for approximately $62.26 million.

The stock lies in the middle of a wide and strong rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 10.98% during the next 3 months and, with a 90% probability hold a price between $24.43 and $27.33 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

EXEL Signals & Forecast

Volume is rising along with the price. This is considered to be a good technical signal. Some negative signals were issued as well, and these may have some influence on the near short-term development. The Exelixis stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. On corrections up, there will be some resistance from the lines at $23.04 and $23.04. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Thursday, March 21, 2024, and so far it has fallen -4.39%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD).

Support, Risk & Stop-loss for Exelixis stock

Exelixis finds support from accumulated volume at $22.09 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

In general the stock tends to have very controlled movements and with good liquidity the risk is considered very low in this stock. During the last day, the stock moved $0.465 between high and low, or 2.04%. For the last week the stock has had daily average volatility of 2.50%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (EXEL) For The Upcoming Trading Day Of Thursday 18th

For the upcoming trading day on Thursday, 18th we expect Exelixis to open at $23.00, and during the day (based on 14 day Average True Range), to move between $22.35 and $23.39, which gives a possible trading interval of +/-$0.517 (+/-2.26%) up or down from last closing price. If Exelixis takes out the full calculated possible swing range there will be an estimated 4.52% move between the lowest and the highest trading price during the day.

Since the stock is closer to the resistance from accumulated volume at $22.98 (0.48%) than the support at $22.09 (3.41%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.

Is Exelixis stock A Buy?

The Exelixis stock holds several negative signals and despite the positive trend, we believe Exelixis will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.

Current score: -2.703 Sell Candidate Unchanged

Predicted Opening Price for Exelixis of Thursday, April 18, 2024

Fair opening price April 18, 2024 Current price
$23.00 ( 0.547%) $22.87

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for EXEL

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 23.46 2.58 %
R2 23.28 1.80 %
R1 23.17 1.32 %
Current price: 22.87
Support S1 22.82 -0.230 %
S2 22.71 -0.710 %
S3 22.53 -1.49 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 23.92 4.59 %
R2 23.68 3.54 %
R1 22.98 0.481 %
Current price 22.87
Support S1 22.09 -3.41%
S2 21.89 -4.29%
S3 20.39 -10.84%

FAQ

What is the symbol for Exelixis Stock and on which exchange is it traded?
The symbol for Exelixis is EXEL and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Exelixis Stock?
The Exelixis stock holds several negative signals and despite the positive trend, we believe Exelixis will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.

How to buy Exelixis Stock?
Exelixis Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Exelixis Stock.

What's the current price of Exelixis Stock?
As of the end of day on the 2024-04-17, the price of an Exelixis (EXEL) share was $22.87.

What is the 52-week high and low for Exelixis Stock?
The 52-week high for Exelixis Stock is $24.34 and the 52-week low is $18.08.

What is the market capitalization of Exelixis Stock?
As of the 2024-04-17, the market capitalization of Exelixis is 6.919B.

When is the next earnings date for Exelixis?
The upcoming earnings date for Exelixis is May 14, 2024.
Click to get the best stock tips daily for free!

About Exelixis

Exelixis Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CA... EXEL Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT